Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Bisphosphonates are a standard treatment for metastatic bone disease, although agents vary in their potential for renal toxicity. This case report describes the reversal of zoledronic acid-induced renal toxicity by switching treatment to ibandronate in a patient with hormone-refractory prostate cancer and bone metastases.
Joensuu
Timo K
TK
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. Timo.Joensuu@hus.fi
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D003404:Creatinine / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008297:Male; D010166:Palliative Care; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D019233:Retreatment; D018570:Risk Assessment; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D003404:Creatinine; D017430:Prostate-Specific Antigen; D000077557:Ibandronic Acid